HE ORDERED REGULATION of human megakaryocytopoiesis is a complex process that involves both soluble mediators, such as cytokines, and direct cell-cell interactions within the bone marrow (BM) microenvironment. Megakaryocytes appear to have a unique maturational program based on their endoreduplication of DNA without cell division, leading to polyploid cells that ultimately form demarcation membranes and release of platelet^.'.^ A number of hematopoietic growth factors including the kit ligan# stem cell factor (KWSCF), interleukin-3 (IL-3), granulocytemacrophage colony-stimulating factor (GM-CSF), and IL-64-" have all been reported to modulate in vitro megakaryocyte progenitor proliferation andor maturation. Furthermore, megakaryocyte interactions with two important marrow stromal elements, fibroblasts and endothelial cells, may respectively result in different branch points in the program of megakaryocyte proliferationI2 and differentiati~n'~ in vitro. Stromal fibroblast adhesion with marrow megakaryocytes leads to transduction of a growth signal, whereas adhesion to endothelial cells may result in promotion of megakaryocyte maturation.
One of the major cell types that constitutes the hematopoietic stroma is the fibroblast. Fibroblasts have long been recognized as playing an active role in the marrow microenvironment, acting as a cell source of a number of growth factors that may act on hematopoietic progenitor^.'^.^^ One of the major products secreted by fibroblasts is basic fibroblast growth factor (bFGF). bFGF is a cationic mitogenic protein, which consists of 154 amino acids and stimulates the growth of fibroblasts and other cell types of vascular, neural, an# or connective tissue origin. Basic fibroblast growth factor (bFGF) is also a chemoattractant for capillary endothelial cells, and an angiogenic factor.16-20 Recently, bFGF has been observed to potentiate the responsiveness of early marrow progenitors to later-acting lineage specific growth factors such as erythropoietin and G-CSF, resulting in increased maturation along erythroid and myeloid lineages r e s p e c t i~e 1 y . l~"~'~~'~~ In addition, the presence of bFGF in human BM and peripheral blood cells, as well as the deposition of bFGF in the extracellular matrix of BM stromal cell cultures, was shown.2' Specifically, megakaryocytes and platelets appeared to contain significant amounts of bFGF by immunofluorescence, whereas weaker staining was noted in immature and mature cells of the granulocyte series2' Megakaryocytes also expressed the bFGF receptors, type 1 (flg) and type 2 (bck). 22 We now report that bFGF appears capable of acting directly upon human and murine BM megakaryocytes as well as their progenitors, to potentiate replication of these cells as well as enhance their adhesion to marrow stromal fibroblasts. Furthermore, bFGF is capable of inducing production of other cytokines from marrow megakaryocytes, providing another potential mechanism for modulation of megakaryocytopoiesis by this growth factor. vitro as previously described." Human IL-3, GM-CSF, IL-6, G-CSF, and IL-1P were kindly provided by Genetics Institute (Boston, MA). bFGF was kindly obtained by Scios Inc (Mountainview, CA). Plateau doses of each factor were determined from dose-response curves and used for culture at the following concentrations: E-6, 10 ng&, L I P , 10 ng/mL; IL-3, 10 nglmL; GM-CSF, 200 ngl m L ; G-CSF, 500 nglmL; and bFGF, 10 ng/mL. All these growth factors are free from any carrier proteins. Neutralizing antibodies for IL-3, GM-CSF, IL-6, transforming growth factor p (TGFP), and IL-Ip were kindly provided by Genetics Institute. Neutralizing rabbit antibodies for bFGF were a generous gift of D r Michael Klagsbrum (Children's Hospital, Boston, MA).
Megakaryocyte progenitor assay. BM was aspirated under sterile conditions in preservative-free heparin using standard techniques under a protocol approved by the Institutional Review Board. Light density nonadherent mononuclear cells were prepared after plastic adherence in a Ficoll-Hypaque gradient (Pharmacia, Piscataway, NJ) and cultured in methylcellulose for megakaryocyte colony-forming unit (CFU-MK) as previously described?.'.'" Adhesion assays. BM stromal fibroblast monolayers were prepared and when semiconfluent, cocultures with primary marrow megakaryocytes were established as previously described." In some cultures, bFGF (10 ng/mL) was added 24 hours before adhesion. The marrow stromal fibroblasts were X-irradiated to prevent their growth while sustaining their viability." Tritiated thymidine incorporation in marrow megakaryocytes adherent to X-irradiated stromal fibroblasts was quantitated as a measure of DNA synthesis in the presence or absence of bFGF. After adhesion in some cultures, marrow megakaryocytes were dislodged from the stromal fibroblasts and quantitated for viable cell number using trypan blue exclusion.
Cytokine secretion. Isolated primary marrow megakaryocytes were cultured in RPM1 1640 + 1% platelet poor plasma in the presence or absence of bFGF (10 ng/mL) for 24 hours (105/mL) under conditions previously described."' Platelet poor plasma was used to avoid TGFP and other granule mediators present in high quantity in serum. Supernatants from these cultures were obtained and assayed for immunoreactive cytokines. Radioimmunoassays for human IL-I@, human GM-CSF, human tumor necrosis factor a (TNFa), and human IL-6 were obtained from R & D Systems (Minneapolis, MN) and used according to the manufacturer's instructions. A standard curve with a cytokine-positive control was run in each assay. The lower limit of detection was determined to be 0.35 pgl mL for IL-6, 1.5 pg/mL for GM-CSF, and 0.3 pg/mL for TNFa and IL-lP. Murine megakaryocyte assays. An assay of murine megakaryocyte progenitor cell populations was performed by culturing IO5
murine BM cells for 8 days at 37°C in a humidified atmosphere of 10% CO2 in the presence or absence of bFGF. Megakaryocytic colonies consisting of three or more cells derived from progenitor cells (CFU-MK) were scored after drying the cultures and staining for acetylcholinesterase as previously d e~c r i b e d .~~-'~ To assess megakaryocyte differentiating activity, a single megakaryocyte growth assay was used.2'.29 This assay quantitates the more mature, committed megakaryoblast that is at a later stage than the CFU-MK. Single cell populations from BM were prepared from the femurs of normal C57B116 mice by flushing the bones with Dulbecco's modified Eagle's medium (DMEM; Cellgro, VA) containing 10% fetal calf serum (FCS). Immature megakaryocyte populations were obtained in 1.07 to 1.085 @cm3 fractions from a suspension of single BM cells separated in a Percoll gradient (Pharmacia). The fractionated cells were cultured in 10% FCS in DMEM for 5 days at 37°C in a humidified incubator in the presence of titrated doses of bFGF. Cultures were dried and stained for acetylcholinesterase; megakaryocyte growth was quantitated by the number of single large megakaryocytes detected by light microscopy.
An indirect immune complex depletion method was used for the neutralization studiesY9 Suboptimal levels of growth factors and optimal levels of antibodies (1 in 10 dilution) were chosen to ensure an antibody excess, mixed and incubated at 4°C for 2 hours. For controls, normal rabbit serum or IgG control were used. Immune complexes were precipitated by adding 50 pL of protein A-sepharose CL-4B (Pharmacia, Uppsala, Sweden). The supernatants were collected and assayed for residual megakaryocyte stimulatory activity in the immature murine megakaryocyte growth assay. Neutralizing MoAbs for human IL-6, IL-la, IL-lp, and GM-CSF were kindly obtained from Genetics Institute (Boston, MA).
Staristical analysis.
The results were expressed as the mean -+ SEM of data obtained from three or more experiments performed in duplicate. Statistical significance was determined using the Student's t-test.
RESULTS

Effect of bFGF on proliferation of immortalized megakaryocytic cell lines.
Human megakaryocytic cell lines were analyzed for their proliferative response to various concentrations of exogenous bFGF. As shown in Fig 1, the megakaryocytic cell lines did not replicate in the presence of added bFGF at various concentrations (1, 10, 100 ng/mL).
Proliferation of CMK and CMK11-5 cell lines were not significantly augmented by combinations of bFGF with the hematopoietic growth factors IL-3, GM-CSF, and IL-6 (data not shown). Similar results were obtained with the M07-e cell line (data not shown). These proliferation assays were initially performed at submaximal concentrations of each growth factor and then at optimal combinations of each growth factor. We did not observe any pronounced enhancement when suboptimal concentrations of these cytokines were used.
Effects of bFGF on CMK maturation. bFGF treatment over a range of concentrations (1, 10, or 50 ng/mL) did not alter CMK cell-surface expression of the surface structures GpIb or GpIIbLIIa that are upregulated during megakaryocyte maturation. No effect on CMK ploidy was observed (data not shown).
Effect of bFGF on proliferation of primary human megakaryocytes. The direct effect of bFGF on megakaryocyte progenitors and mature megakaryocytes was evaluated. CFU-MK derived colonies (CD34+ DR+) appeared in the presence of IL-3 and GM-CSF, but not in the presence of IL-6 or bFGF (P < .05) ( Table 1 ). The addition of IL-3 plus bFGF or GM-CSF plus bFGF resulted in the same number of CFLJ-MK as that stimulated by IL-3 or GM-CSF alone. However, the size and number of cells per colony were increased significantly (P < .05) in the presence of bFGF (Table 1 ). IL-6 has no effect on CFU-MK formation, and therefore, can not substitute for bFGF. Furthermore, IL-6 in the presence of IL-3 failed to enhance the formation of CFU-MK (Table 1 ). The effect of bFGF to increase the size and number of CFU-MK-derived colonies in the presence of IL-3 was abolished only by specific antibodies for bFGF and was not affected by either specific antibodies for IL-6, TGFP, and IL-10 (Table l) , indicating a direct specific effect of bFGF on CFU-MK.
The effects of bFGF alone or in combination with IL-3, GM-CSF, and IL-6 on the proliferation of identifiable mar- with BM stromal fibroblasts resulted in adhesion of the normally nonadherent megakaryocytic cells to the fibroblast monolayer. Pretreatment of primary megakaryocytes or stromal fibroblasts with bFGF resulted in enhanced adhesion (Fig 2A) . Interestingly, a potent effect of bFGF on megakaryocytic proliferation was observed when the stromal fibroblasts, as well as the megakaryocytes, were cocultured and treated with this growth factor (Fig 2A) . The proliferative effect required prolonged incubation of the megakaryocytes with the bFGF (24 hours), whereas a more modest effect was seen with shorter incubation times (6 hours) ( Fig   2B) . No effects were seen in this system on megakaryocyte differentiation as measured by propidium iodide staining for DNA content and fluorescence-activated cell sorter (FACS) analysis of expression of surface gpTb and gpITb/IIIa (data not shown).
Efects of bFGF on cytokine secretion by primary BM megakaryocytes. To evaluate whether bFGF might act to induce cytokines from megakaryocytes that modulate human megakaryocytopoiesis, marrow megakaryocytes ( 105/mL) were treated with bFGF (10 ng/mL) for 24 hours. Using specific cytokine assays, supernatant from cultured megakaryocytes, untreated or treated with bFGF, were assayed for synthesis and secretion of human IL-6, IL-l/?, GM-CSF, and TNFa.
IL-6 was detected in the megakaryocyte supernatants as early as 12 hours after bFGF stimulation and increased dur- ing the first 24 hours; about 57 pg/mL of IL-6 from cultured megakaryocyte supernatants was measured ( Table 3 ). The addition of bFGF (10 ng/mL) elicited an increase of IL-6 in all cultures examined to about 96 pg/mL.
Secretion of IL-lp and GM-CSF proteins by human megakaryocytes was also evaluated by using specific IL-lp and GM-CSF enzyme-linked immunosorbent assay (ELISA). No significant effect of bFGF on secretion of GM-CSF and ILlp was observed (Table 3) .
No TNFa protein was detected in the supernatants of unstimulated human megakaryocytes. Small amounts of TNFa (about 11 pg/mL) were detected in cultures of megakaryocyte supernatants treated with bFGF. Taken together, these results indicate that bFGF may enhance mainly the secretion of IL-6 and TNFa by primary human megakaryocytes.
Effect of bFGF on murine megakaryocytopoiesis. The responsiveness of immature murine megakaryocytes to titrated doses of bFGF is shown in Table 4 . Immature megakaryocytes showed a significant response to bFGF with an increase in detectable numbers of acetylcholinesterase-positive megakaryocytes using the single cell growth assay (Table 4). This activity was abolished by specific antibodies for bFGF. The addition of bFGF to IL-6 resulted in a significant increase in the numbers of immature megakaryocytes ( Table   4 ). The effect of bFGF on single cell assay was partially neutralized (about 40%) by specific antibodies for IL-6, and IL-lp ( Table 4 ). The activity of bFGF was not affected by specific antibodies for IL-la. Interestingly, the activity of bFGF was completely abolished by specific antibodies for IL-6 in combination with IL-10.
The effect of bFGF on murine CFU-MK was characterized. bFGF failed to stimulate murine CFU-MK (Table 5 ). The addition of bFGF to cultures containing IL-3 or GM-CSF significantly (P < .05) increased the CFU-MK formation (Table 5 ). This effect was abolished by specific antibod- cultures. Each antibody was assayed in separate experiments with at least two experiments performed for each antibody. All stimulators were assayed at suboptimal concentrations, and antibodies were used at levels that fully neutralized the preparation against which it was raised.
Results were significantly different ( P < ,011 from FCS control. t Significantly different ( P < .01) from nonimmune serum.
the inhibitory response to TGF/3.3' These observations led us to study whether bFGF was capable of altering not only progenitor cell responsiveness but mature lineage-committed mmow megakaryocytes as well. Recently, while our studies were in progress, Bruno et a132 have reported that bFGF promoted the proliferation of human megakaryocyte progenitor cells.
Similar to their results, we observed that the effect of bFGF differed according to the megakaryocytic cell population assayed. The effect of bFGF on CFU-MK was different compared with the effect on more mature megakaryocytes. bFGF significantly enhanced the size of the human CFU-MK and cell numbers per colony. This effect was specific for bFGF and was not affected by anti-TGFP, anti-IL-6, or anti-IL-lp neutralizing antisera. In the murine system, bFGF significantly potentiated CFU-MK formation in the presence of IL-3 or GM-CSF. The different effects of bFGF on human and murine CFU-MK assays could be caused by the preselection of human BM CD34+ DR+ population, whereas murine BM cells without any selection were used in the murine.
bFGF may also modulate other aspects of murine megakaryocytopoiesis. Immature megakaryocytes showed a significant response to bFGF with an increase in detectable numbers of acetylcholinesterase-positive megakaryocytes as shown by the murine single megakaryocyte growth assay. The effect of bFGF was abrogated by rabbit anti-bFGF antibodies or a combination of anti-IL-6 and anti-IL-lp antibodies. These results are in agreement with the previously reported mechanism of bFGF enhancing secretion of IL-6 ies for IL-3 and GM-CSF respectively. No significant effect of IL-6 was observed when added to IL-3 on CFU-MK formation. These results indicate the dominant effect of bFGF in CFU-MK-derived clones in the presence of IL-3 or GM-CSF.
DISCUSSION
Although bFGF was initially characterized as a growth factor for mesenchymal cells, this cytokine can modulate the response of hematopoietic CD34+ progenitor cells to lateracting lineage specific growth factors such as erythropoietin and G-CSF. Based on the studies presented here, it appears that bFGF is also capable of potentiating the response of human megakaryocyte progenitors (CFU-MK) in terms of increasing the proliferative capacity of such progenitors to form colonies of greater cell number. This result builds upon a previous report on the expression of the bFGF receptor in human megakaryoblasts.21.22 Furthermore, bFGF was shown to reduce zidovudine toxicity of CFU-MK from normal murine and human marrow cells.30 In addition, bFGF significantly abrogated the inhibitory effect of TGFp on GM-CSF?' which might indicate a role for bFGF in modulating Results are the means ? SEM from triplicate cultures from three experiments. CFU-MK megakaryocytes were scored as the number of colonies with 3 cells or more per IO6 unfractionated cells. Each antibody was assayed in separate experiments with at least two experiments performed for each antibody. All stimulators were assayed at suboptimal concentrations, and antibodies were used at levels that fully neutralized the preparation against which it was raised.
Results were significantly different ( P < .01) from FCS control. t Significantly different ( P < .01) from nonimmune serum.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From by human megakaryocytes, and with the observations of Bikfalvi et al. " We were intrigued to find that bFGF was able to increase secretion of IL-6 and TNFa. Release of such cytokines from human megakaryocytes could contribute to an autocrine pathway as well as modulate other hematopoietic elements. Although TNFa may be inhibitory, particularly for erythroid progenitors, IL-6 is known to be a potent stimulus of megakaryocyte development.' Given the growth potentiating effects of bFGF, the effect of an inhibitor like TNFa might be ovemdden by the stimulatory effect of IL-6.
We extended our in vitro models of cells in suspension culture to study the interaction of marrow megakaryocytes with marrow stromal fibroblasts because such adhesion to stromal elements is believed to be an important aspect of hematopoiesis. There was a complex in vitro interaction observed between these cell types. As previously described, marrow stromal fibroblasts are important constitutive sources of KUSCF and are able to potentiate megakaryocyte proliferation in vitro without exogenous bFGF.'* Thus, it was interesting to observe that stimulation of marrow megakaryocyte proliferation could be augmented by addition of bFGF to marrow megakaryocytes adherent to X-irradiated fibroblasts. Because the marrow fibroblasts were X-irradiated in these cocultures, the observed increase in DNA synthesis reflected changes in the megakaryocyte rather than the stromal fibroblast. Whether this proliferative response was caused by release of other cytokines from the stromal fibroblast, the adherent megakaryocyte, or both, or whether adherent megakaryocytes have a different capacity for response to certain ligands compared with nonadherent megakaryocytes are issues that require further study. Although this in vitro model system may appear complex, it begins to more closely approximate certain elements of the in vivo BM microenvironment in which the megakaryocyte proliferates and matures and thus may reflect more closely the physiologic roles of growth factors such as bFGF.
It appears that bFGF is able to modulate the program of megakaryocytopoiesis both at the progenitor and mature cell levels. In this way, it resembles the KUSCF."*" Further definition of the physiologic roles and potential therapeutic uses of bFGF in megakaryocytopoiesis may be assisted by experiments involving immunodeficient mice engrafted with human progenitor cells,33 as well as studies in animal models such as primates.
